Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | CCKAR | P32238 | 10/20 | 0.45 |
| ▸ | CCKBR | P32239 | 10/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12686625 | 0.91 | GLP1R (0.58) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL10052653 | 0.91 | GLP1R (0.56) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL10052635 | 0.91 | GLP1R (0.60) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL10052652 | 0.91 | GLP1R (0.60) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL10052636 | 0.91 | GLP1R (0.60) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL18891602 | 0.89 | GLP1R (0.61) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL20567478 | 0.89 | GLP1R (0.54) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL20567479 | 0.89 | GLP1R (0.54) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL10052714 | 0.89 | GLP1R (0.54) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL433024 | 0.89 | GLP1R (0.54) | GLP1RFOLH1CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190232-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | NOVO NORDISK A/S (DK) | 2013-07-25 | — | — | US | claimed |
| EP-2595647-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | Novo Nordisk A/S (DK) | 2013-05-29 | — | — | EP | claimed |
| WO-2012010553-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | WO | claimed |
| US-9655974-B2 | N-terminal modified FGF21 compounds | NOVO NORDISK A/S (DK) | 2017-05-23 | — | — | US | disclosed |
| US-20130190232-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | NOVO NORDISK A/S (DK) | 2013-07-25 | — | — | US | disclosed |
| EP-2595647-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | Novo Nordisk A/S (DK) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010553-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190232-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | FABP1, LIPC, GLP1R | GLP1R 3/4885FOLH1 1645/4885CCKAR 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.